News

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...
pharmaphorum1d
Data at EULAR back Biogen, UCB's first-in-class lupus drug
Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...
Nasdaq2d
UCB & Biogen : Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal
(RTTNews) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate.
Nasdaq2d
UCB and Biogen Announce Positive Efficacy Results for Dapirolizumab Pegol in Phase 3 PHOENYCS GO Study for Systemic Lupus Erythematosus
UCB is listed on Euronext Brussels (symbol: UCB). Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s ...
MedPage Today on MSN2d
First-in-Class Lupus Drug Aces Phase III Test
BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...
Finanznachrichten2d
Biogen Inc.: Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
10 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen. 11 About UCB UCB ...
Hosted on MSN23d
Merck KGaA’s lupus drug to advance to Phase III despite mixed data
In September 2024, UCB and Biogen announced their lupus drug dapirolizumab pegol had met its primary endpoint in a Phase III trial, with data later shared in November in an oral, late-breaker ...
BMJ8d
ASAS consensus definition of early axial spondyloarthritis
Objectives To develop a consensual definition for the term ‘early axial spondyloarthritis—axSpA’—and ‘early peripheral spondyloarthritis—pSpA’. Methods The ASAS (Assessment of SpondyloArthritis ...
Biogen (BIIB) Receives a Hold from Wedbush
In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...